What are the characteristics of MEDINCELL stock?

MEDINCELL is a company operating in the Santé · Biotechnologies · Pharmacie sector. The stock is listed on Euronext Paris under ISIN FR0004065605.

What is the recent price evolution of MEDINCELL stock?

Since last close: 0.69 %. Over one week: -3.88 %. Over one year: 55.78 %.

Medincell Stock Up 4.46% at Opening

Published on Dec 08, 2025 at 10:09

MEDINCELL

23.32 € +0.69 %

Medincell shares started off strongly this Monday morning, gaining 4.46% to settle at €27.16. This improvement contrasts with the weekly trend, which saw a decline of 3.55%. However, it is part of a broader upward trend, with a gain of 60.33% over three months and 62.05% over a year, significantly outperforming the CAC 40 (+8.83% annually). Trading volumes remain moderate, representing 0.13% of the capital.

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

The RSI index at 20 indicates an oversold zone, which could explain the technical rebound observed this morning. Additionally, the stock is significantly above its 200-day moving average (€19.73), confirming a structural bullish momentum, but below the key resistance of the MM50 (€30.64), indicating a short-term consolidation phase.

🏢 Other stocks — Santé

🗞️ OSE Immuno Shares Soar 21% Following Key FDA Designation 🗞️ DBV Technologies Stock Rises Against the Trend in the Health Sector This Monday 🗞️ Eurofins Scientific Shares Gain 2.27% Following Massive Buyback 🗞️ EMEIS Appoints Jean-Marc Boursier as Deputy CEO Effective July 1

Context

Period

Period: 9M 2025

Guidance from the release

We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.

Risks mentioned

Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)

Opportunities identified

Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Context

Also read